Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue  Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System San Francisco, CA -- July 12, 2022 -- InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is furthering progress in discussions with investors and developing the financing model towards the next step of the development process with its Nanoemulsion drug delivery system.   The Company...
Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System   San Francisco, CA -- June 29, 2022 -- InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK: ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to be reviewing the financing for taking the steps on moving forward with its development process of the Nanoemulsuion Drug Delivery System. Many anticancer drugs have been disco...
Oncology Pharma Announces: Initial Feasibility Study of the Nanoemulsion Drug Delivery System is Complete and Results Have Met the Threshold for Moving Forward To the Next Steps of Development   SAN FRANCISCO, CA -- June 8, 2022 -- InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK: ONPH) - Oncology Pharma, Inc. ("The Company") is pleased that the initial feasibility stage is complete and results have met the threshold to move forward. The formulation under dev...
Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development      San Francisco, CA -- May 9, 2022 -- InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK: ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to execute its next phase with Connect2Trials, Inc.  Originally, the Company engaged with Ribera Solutions, Inc.'s "Connect2Med" on its patient engagement pl...
Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat CancerSan Francisco, CA -- April 13, 2022 -- InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma ("The Company") is pleased to announce that it has completed the initial feasibility phase of its licensed dactinomycin nanoemulsion.  The successful completion of the feasibility stage marks the initial planned milestone for this development project.  Data is currently und...

Oncology Pharma Reports on Progress with Ribera Solutions

01:03pm, Wednesday, 02'nd Mar 2022 InvestorsHub
SAN FRANCISCO, CA -- March 2, 2022 -- InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK: ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to announce progress with its investment with Ribera Solutions' Connect2Med.  Ribera has segregated the business entity into a separate business unit and made it an independent entity as a Delaware Corporation under the name of Connect2Trials, Inc.  Oncology Pharma's investment has been transferred to the new business and it has committed to furt...
SAN FRANCISCO, CA -- February 23, 2022 -- InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK: ONPH) - Oncology Pharma, Inc. ("The Company") looks toward releasing further results of the studies under the Co-Development Agreement with NanoSmart Pharmaceuticals, demonstrating the feasibility and the time release characteristic that is expected to improve the safety and localization profile of the eventual lead candidate formulations.The active pharmaceutical ingredient, dactinomycin is an act...

Oncology Pharma Expands on Feasibility Studies and Data

01:16pm, Thursday, 17'th Feb 2022 InvestorsHub
SAN FRANCISCO, CA -- February 17, 2022 -- InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") wants to expand on a previously announced press release that included results of formulations and data on licensed technology with NanoSmart Pharmaceuticals demonstrating the time release characteristic that is expected to improve the safety and localization profile of the eventual lead candidate formulations.   The acti...
San Francisco, CA -- February 14, 2022 -- InvestorsHub NewsWire -- Oncology Pharma, Inc. ("The Company") (OTC PINK:ONPH) and Regen BioPharma, Inc. (OTC PINK:RGBP) and (OTC PINK:RGBPP): announced that they intend to work jointly to fast track the development of therapeutic uses related to treatment in humans with pancreatic cancer of Regen's patented ANTIGEN SPECIFIC MRNA CELLULAR CANCER VACCINES  ("MRNA Vaccines"). In April of 2021 ONPH was granted an exclusi...
SAN FRANCISCO, CA – February 8, 2022 – InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK: ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to announce that the co-development agreement and ongoing work to advance the licensed technology with Nanosmart has identified that the formulations demonstrate the time-release characteristic that is expected to improve the safety and localization profile of the eventual lead candidate formulation(s).  Data prov...

Oncology Pharma's New Year Update

01:15pm, Monday, 10'th Jan 2022 InvestorsHub
SAN FRANCISCO, CA -- January 10, 2022 -- InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK: ONPH) - Oncology Pharma, Inc. ("The Company") update on its progress to kick off the new year.    The Company has advanced its relationship and made further investment into Ribeira Solutions' Connect2Med, a patient engagement platform utilizing latest available technologies.  Connect2Med provides a motivating trial experience through increased engagement...

Oncology Pharma Meeting Towards Future Developments

01:11pm, Friday, 17'th Dec 2021 InvestorsHub
San Francisco, CA -- December 17, 2021 -- InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC: ONPH) Oncology Pharma, Inc. ("The Company") conducted a meeting with the Board of Directors, executives, and Scientific Advisory Board members along with legal counsel, which shared updates on progress made towards the development of the Company's licensed products.  This marked progress towards pursuing its primary goal of the Co-Development plan to bring new pharmaceu...

Oncology Pharma Year End Review and Outlook

01:04pm, Thursday, 09'th Dec 2021 InvestorsHub
  Oncology Pharma Year End Review and Outlook   SAN FRANCISCO, CA -- December 9, 2021 -- InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK: ONPH) - Oncology Pharma, Inc. ("The Company") and its Chief Executive are pleased to give a year end update and provide an outlook for what to look for in the coming months and year ahead.  The Company is proud of the progress it has made this past year including the addition of a  renownrenowned Chai...

Oncology Pharma Research and Vision

01:02pm, Tuesday, 30'th Nov 2021 InvestorsHub
San Francisco, CA -- November 30, 2021 -- InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is a pioneering oncology company dedicated to providing the financing and the tools to license, develop, manufacture, and commercialize therapeutics. The Company has assembled a team of executives and advisors with proven multi-disciplinary expertise in the fields of oncology and therapeutics with leadership to identify, n...
SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Pursuant to previously announced press release, Oncology Pharma, Inc. (the "Company") has retained the services
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE